Daiichi Sankyo Company, Limited (4568.T)
| Previous close | 5,091.00 |
| Open | 5,090.00 |
| Bid | 5,132.00 x N/A |
| Ask | 5,139.00 x N/A |
| Day's range | 5,076.00 - 5,191.00 |
| 52-week range | 3,566.00 - 6,257.00 |
| Volume | |
| Avg. volume | 4,524,909 |
| Market cap | 9.763T |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 42.92 |
| EPS (TTM) | 119.65 |
| Earnings date | 29 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | 60.00 (1.17%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | 6,321.40 |
- Business Wire
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
TOKYO & BASKING RIDGE, N.J., September 15, 2024--Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumors known to express Claudin-6 (CLDN6). These data were presented today during a Proffered Paper session (610O) at the 2024 European Society for Medical Oncology (#ESMO24).
Business WireENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
TOKYO & BASKING RIDGE, N.J., September 13, 2024--ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
Business WireDatopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., September 09, 2024--Detailed results from the TROPION-Lung01 phase 3 trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Results will be presented today during an oral presentation (OA08
